n CME : Your SA Journal of CPD - Medifile

Volume 21, Issue 6
  • ISSN : 0256-2170



Extracted from text ... 354 C M E J u n e 2 0 0 3 Vo l . 2 1 No . 6 MEDIFILE MSP (Merck/Schering-Plough) received US FDA a p p r oval on 25 October 2002 for Zetia, the first new class of lipid-lowe ring drugs approved since the stat i n s were launched 15 ye a rs ago. DIFFERENT MECH A NISM OF AC T ION E z e t i m i b e , the active ingredient in Zetia, is a s e l e c t i ve cholesterol absorption inhibitor, acting at the brush border ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error